Panobinostat (LBH589)

Name: Panobinostat (LBH589)
Brand: Selleck Chemicals
SKU: S1030
Rating: 5 (252 reviews)

For research use only.

Catalog No.S1030 Synonyms: NVP-LBH589

252 publications

Panobinostat (LBH589) Chemical Structure

CAS No. 404950-80-7

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.

Selleck's Panobinostat (LBH589) has been cited by 252 publications

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 36(5):528-544

PubMed: 31631026 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):782-797

PubMed: 31085178 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Nat Genet, 2018, 50(10):1442-1451

PubMed: 30224647 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cell, 2014, 20;159(5):1110-1125.

PubMed: 25416949 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Blood, 2020, 10.1182/blood.2019004332

PubMed: 32844992 ( click the link to review the publication )

Nat Commun, 2020, 11(1):583

PubMed: 31996670 ( click the link to review the publication )

Sci Immunol, 2020, 5(50):eabb5168

PubMed: 32826342 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33046

PubMed: 32599665 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):105

PubMed: 32517809 ( click the link to review the publication )

Cancers (Basel), 2020, 5;12(6):E1478

PubMed: 32517016 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2857

PubMed: 33023028 ( click the link to review the publication )
PLoS Pathog, 2020, 16(3):e1008442

PubMed: 32196533 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32059481 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1827-1843

PubMed: 32642294 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3470

PubMed: 32103105 ( click the link to review the publication )

Fluids Barriers CNS, 2020, 2;17(1):37

PubMed: 32487241 ( click the link to review the publication )

Exp Hematol, 2020, 81:32-41

PubMed: 31954171 ( click the link to review the publication )

J Thromb Haemost, 2020, 10.1111/jth.15012

PubMed: 32662223 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04021-y

PubMed: 31894347 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4393-4405

PubMed: 32926125 ( click the link to review the publication )

EBioMedicine, 2020, 102853

PubMed: 32654992 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01408-7

PubMed: 32733069 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4429-4439

PubMed: 32606937 ( click the link to review the publication )

Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )

Commun Biol, 2020, 3(1):363

PubMed: 32647372 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

J Med Chem, 2020, 10.1021/acs.jmedchem.9b01888

PubMed: 32803970 ( click the link to review the publication )

Cell Res, 2019, 29(4):286-304

PubMed: 30631154 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3319

PubMed: 31346162 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )
Neuro Oncol, 2019, 10.1093/neuonc/noz215

PubMed: 31711240 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):185

PubMed: 31053152 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):134

PubMed: 31801577 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1666-1676

PubMed: 30954557 ( click the link to review the publication )

J Biomed Nanotechnol, 2019, 15(5):979-992

PubMed: 30890229 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Biomolecules, 2019, 9(5)

PubMed: 31083537 ( click the link to review the publication )
J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18970-18984

PubMed: 30916359 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

J Virol, 2019, 93(24)

PubMed: 31578289 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(2)

PubMed: 30455231 ( click the link to review the publication )

Epigenetics Chromatin, 2019, 12(1):18

PubMed: 30871586 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Mol Carcinog, 2019, 58(12):2230-2240

PubMed: 31478563 ( click the link to review the publication )

Mol Carcinog, 2019, 58(2):234-246

PubMed: 30303565 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

Mol Genet Genomic Med, 2019, 7(5):e613

PubMed: 30891950 ( click the link to review the publication )

Childs Nerv Syst, 2019, 35(5):823-831

PubMed: 30815722 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4866

PubMed: 30451831 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )
Oncogene, 2018, 37(6):722-731

PubMed: 29059175 ( click the link to review the publication )

Cancer Lett, 2018, 417:152-160

PubMed: 29306016 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):381-392

PubMed: 28839000 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1705-1716

PubMed: 29748211 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(2):201-212

PubMed: 29260509 ( click the link to review the publication )

J Immunol, 2018, 201(3):1086-1096

PubMed: 29914885 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9472

PubMed: 29930256 ( click the link to review the publication )

J Proteome Res, 2018, 17(4):1436-1451

PubMed: 29564889 ( click the link to review the publication )

Biomed Pharmacother, 2018, 100:509-520

PubMed: 29494986 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

J Ethnopharmacol, 2018, 211:267-277

PubMed: 28970153 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):196-207

PubMed: 29317217 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0208147

PubMed: 30592723 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(1):61-74

PubMed: 29049036 ( click the link to review the publication )
PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36530-36541

PubMed: 30559935 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28586-28598

PubMed: 29983882 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 100(1):174-187

PubMed: 29107335 ( click the link to review the publication )

Nat Commun, 2017, 8(1):728

PubMed: 28959017 ( click the link to review the publication )

Cancer Res, 2017, 77(11):3027-3039

PubMed: 28363998 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

Stem Cell Reports, 2017,

PubMed: 29033304 ( click the link to review the publication )

Cell Death Dis, 2017,

PubMed: 29022919 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Arch Toxicol, 2017, 91(1):365-391

PubMed: 27015953 ( click the link to review the publication )

Arch Toxicol, 2017, 91(2):839-864

PubMed: 27188386 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Br J Haematol, 2017, 178(5):728-738

PubMed: 28480959 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Int J Nanomedicine, 2017, 12:1385-1399

PubMed: 28260886 ( click the link to review the publication )

J Biol Chem, 2017, 292(9):3683-3691

PubMed: 28087699 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017,

PubMed: 29136455 ( click the link to review the publication )

Exp Cell Res, 2017, 350(1):218-225

PubMed: 27914787 ( click the link to review the publication )
Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169485

PubMed: 28052119 ( click the link to review the publication )

Horm Cancer, 2017, 8(4):257-267

PubMed: 28516379 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1575-1583

PubMed: 29296798 ( click the link to review the publication )

Genom Data, 2017, 12:14-16

PubMed: 28239551 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30019-30029

PubMed: 28415789 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56747-56757

PubMed: 28915627 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94569-94579

PubMed: 29212250 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:127-148

PubMed: 27761818 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Oncogene, 2016, 35(46):6026-6037

PubMed: 27157610 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2016, 3:16003

PubMed: 27626039 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )
Sci Rep, 2016, 6:30749

PubMed: 27480951 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

Retrovirology, 2016, 13(1):36

PubMed: 27206407 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Am J Transl Res, 2016, 8(9):3893-3902

PubMed: 27725868 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

J Org Chem, 2016, 81(22):11324-11334

PubMed: 27768313 ( click the link to review the publication )

JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27769045 ( click the link to review the publication )

Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Biomaterials, 2015, 73:110-9

PubMed: 26406451 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 26294211 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Arch Toxicol, 2015, 89(9):1599-618

PubMed: 26272509 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

Mol Pharm, 2015, 12(7):2469-76

PubMed: 26030093 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )
J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(12):1784-93

PubMed: 26529495 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0126566

PubMed: 26176219 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134426

PubMed: 26247786 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Exp Hematol, 2015, 43(6):448-61

PubMed: 25704054 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2088-100

PubMed: 25576920 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )

Br J Cancer, 2014, 111(2):281-91

PubMed: 24946002 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

Mol Carcinog, 2014, 53(9):722-35

PubMed: 23475695 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )
PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1325-34

PubMed: 23515752 ( click the link to review the publication )

PLoS One, 2013, 8(8):e74253

PubMed: 23991216 ( click the link to review the publication )

PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )
Genet Mol Res, 2013, 12(4):5405-13

PubMed: 24301913 ( click the link to review the publication )

The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

J Neurooncol, 2012, 110(3):335-48

PubMed: 23054560 ( click the link to review the publication )

Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. ^[1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	NVHjb29PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\0Uow6OC1zMDFOwG0>	NXj5doE4OC12IHS=		MnTKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M1nnOVI3PzB{N{i0
HepG2	NUnC[Y5pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7iSWU6OC1zMDFOwG0>	MnHBNE01KGR?		NHvNeVNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MkXrNlY4ODJ5OES=
HT29	MWHGeY5kfGmxbjDBd5NigQ>?	NXXCV5NzPTEEoH7N	MWSyOE04OiCq		NYDxWXhucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB2ONMgbOKh	NULT[Yk1OjZ5MEK3PFQ>
HepG2	MVTGeY5kfGmxbjDBd5NigQ>?	M2L5XVUxyqCwTR?=	MoDSNlQuPzJiaB?=		NX\RZo9qcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB{NNMgbOKh	MnPNNlY4ODJ5OES=
HCC827	NU[3SpN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXETnY6PS95LkWvNVAhdk1?	M{PBcVczyqCq	M1Hyd2ROW09?	M3\PRoVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk	MVuyOlY4PTR6NB?=
A549	NV\QOG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXIb4N2OTBxMUWvNlAhdk1?	M3\1PFczyqCq	NGPXNHdFVVOR	NF\zcGVmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?=	M164U\|I3Pjd3NEi0
NCI-H460	NVS4O2xzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LTfVExNzJyL{OwJI5O	NU\Jd2ZqPzMEoHi=	NGrMdFhFVVOR	MV;lcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>?	NVzFZ21oOjZ4N{W0PFQ>
J89GFP	NUPmeG5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NELqboZFVVORwrC=	NXfRW\|lJTUN3ME20PU45PSEEsTCxNk43PSCwTR?=	MVuyOlU3OzV4OB?=
THP89GFP	MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIe1UHFFVVORwrC=	MYnFR\|UxRTF7LkO0JOKyKDZwNEOgcm0>	M37LV\|I3PTZ\|NU[4
SK-NEP-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPScHIxNjBz4pETNVAvOCEQvF2=	NGrjcHozPCCq	MnjaSG1UV8Li	M2S3VGlEPTB;N{[uN\|Qhdk1?	MlvkNlYyPzZ{MUm=
G401	M1vFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrGNE4xOeLCk{GwMlAh\|ryP	NGHZU\|czPCCq	MlrkSG1UV8Li	M3G3V2lEPTB;MUSzMlAzKG6P	MnvYNlYyPzZ{MUm=
SK-NEP-1	MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NVjuS2IyPTBibl2=	NHzMfIoy6oDVNDDk	MnjZSG1UV8Li	M37IZ5Jm\HWlZYOgZ4VtdCC\|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>?	NWrxVJk6OjZzN{[yNVk>
G401	MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MYi1NEBvVQ>?	MlfJNgKBmzRiZB?=	Mkn6SG1UV8Li	MY\y[YR2[2W\|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	Mm[xNlYyPzZ{MUm=
SK-NEP-1	MVfBdI9xfG:\|aYOgRZN{[Xl?	Ml3QOVAwOTByIH7N	NYLSSGQyOjRiaB?=	M1L2dWROW00EoB?=	NGHCUZRqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MYOyOlE4PjJzOR?=
G401	MUPBdI9xfG:\|aYOgRZN{[Xl?	NWHKWIs4PTBxMUCwJI5O	MYeyOEBp	M32yU2ROW00EoB?=	MnP2bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MWGyOlE4PjJzOR?=
SK-NEP-1	NIXpbGJHfW6ldHnvckBCe3OjeR?=	NEHk[og2OC9zMECgcm0>	MkXwNlQhcA>?	MoPlSG1UV8Li	MW\zbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v	NVP0Xm1JOjZzN{[yNVk>
G401	M2TORWZ2dmO2aX;uJGF{e2G7	M2K5dFUxNzFyMDDuUS=>	NFH0SHEzPCCq	NILhZVdFVVORwrC=	M4L4eZNpd3e\|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25?	NXnCcXh6OjZzN{[yNVk>
SK-NEP-1	MU\GeY5kfGmxbjDBd5NigQ>?	NIG1flM2OC9zMECgcm0>	M4nlVFI1KGh?	MWrEUXNQyqB?	MVjpcoR2[2W\|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=>	NHrONGkzPjF5NkKxPS=>
G401	NIHKZnpHfW6ldHnvckBCe3OjeR?=	NHnwVXg2OC9zMECgcm0>	NWHFZndzOjRiaB?=	M3jUZ2ROW00EoB?=	NGPvNHVqdmS3Y3XzJINmdGxiY4njcIUh\Gm\|b4Lk[ZLDqA>?	M4P5SlI3OTd4MkG5
RPMI 8226	NYLPbnk6S2WubDDTeZJ3cX[jbDDBd5NigQ>?	NHHUOHEzNzRxNjDuUS=>	MWq0PQKBkWh?		NGLoUmNqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq	NFvnT2QzPjByMEK5Ni=>
OPM2	NFvUWWNE\WyuIGP1dpZqfmGuIFHzd4F6	MXSyM\|QwPiCwTR?=	MoLEOFjjiImq		NH;qdmJqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq	NHvkOGUzPjByMEK5Ni=>
U266	MV7D[YxtKFO3co\peoFtKEG\|c3H5	M4O5TVIwPC94IH7N	MVy0PQKBkWh?		NFvlfopqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq	NGrFXVMzPjByMEK5Ni=>
H929	M3LP[GNmdGxiU4Xyeol3[WxiQYPzZZk>	MoC2Nk81NzZibl2=	MYi0PQKBkWh?		MnPObY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>?	MVGyOlAxODJ7Mh?=
RPMI 8226	NEXJWpRCeG:ydH;zbZMhSXO\|YYm=	MlPYOQKBkW6P	NVvrVYs4OjRxNEigbC=>		MkLqbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MUWyOlAxODJ7Mh?=
HCC827	Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojKNVAhdk1?	M2Pyd\|Q5KGh?	NF\qbJFFVVOR	Ml7l[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB?	M3\qe\|I2QTR2NkG3
NCI-H23	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nWVVExKG6P	MY[0PEBp	NVuzR3h[TE2VTx?=	MVLlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>?	NIG3fY4zPTl2NE[xOy=>
AML3	NFfIVotHfW6ldHnvckBCe3OjeR?=	M2TySFAuOSEQvF2=	NWG4Oo5oOjUEoHi=		M4rp[4lv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NHrDNYwzPTZzMkm0NS=>
ML-1	MkLpSpVv[3Srb36gRZN{[Xl?	MXKwMVEh\|ryP	NYnt[XlPOjUEoHi=		MU\pcoR2[2W\|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MnrENlU3OTJ7NEG=
RPMI-8226vr10	MYPGeY5kfGmxbjDBd5NigQ>?	MYGwMVEh\|ryP	MYOyOOKhcA>?		MXXpcoR2[2W\|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M2LsOFI2PjF{OUSx
ML-1	NGjNdGhHfW6ldHnvckBCe3OjeR?=	NGjOPG4yKM7:TR?=	NYTONWNsOjUEoHi=		NG\3WJVqdmO{ZXHz[ZMh[2G\|cHHz[U0{KGGldHn2bZR6KDRvZn;s[C=>	Ml\iNlU3OTJ7NEG=
RPMI-8226vr10	NWLad\|B1TnWwY4Tpc44hSXO\|YYm=	MmHRNUDPxE1?	NXXHOXNzOjUEoHi=		NYLPZ3RicW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB{LkWt[o9t\A>?	NGXh[4wzPTZzMkm0NS=>
SK-N-BE (2)	NFq2dJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX2yOQKBkWh?		MofBTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P	MkjONlU{ODh7MU[=
SK-N-BE (2), PAN MK	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFGxWWczPOLCiXi=		MlLxTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P	NHTN[\|kzPTNyOEmxOi=>
SK-N-BE (2), MK PAN	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV6yOQKBkWh?		MorSTWM2OD1\|OEKuNQKBkcLz4pEJOFMvOiCwTR?=	NYT3N3B2OjV\|MEi5NVY>
SK-N-AS	M2q0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4jCfVI16oDLaB?=		NViwS4NQUUN3ME2zO{4y6oDLwsJihKkzNjRibl2=	MU[yOVMxQDlzNh?=
SK-N-DZ	MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2HUO\|I16oDLaB?=		M37DPGlEPTB;MUeuNgKBkcLz4pEJNE41KG6P	NEXjU5QzPTNyOEmxOi=>
Caki-1	NH3yfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInQeIgyOC9{NT:1NEBvVQ>?	NX\2c3BOPDhiaB?=		Mn2xbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{	MXuyOVI4QTF7MR?=
ACHN	MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLDNVAwOjVxNUCgcm0>	M3vsUFQ5KGh?		NIPEeZpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	M{H6SVI2Ojd7MUmx
769-P	NUTOTGdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYi1N\|FjOTBxMkWvOVAhdk1?	NWHLW\|RXPDhiaB?=		MlHpbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{	NIXwb\|YzPTJ5OUG5NS=>
786-O	MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fPUlExNzJ3L{WwJI5O	Mly3OFghcA>?		NGrsWJVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	M4TsdFI2Ojd7MUmx
Caki-1	NWDtbFFuSXCxcITvd4l{KEG\|c3H5	M2XIO\|UxKG6P	M13tfVQ5KGh?		NITxfItqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	Moi2NlUzPzlzOUG=
ACHN	M33PUGFxd3C2b4Ppd{BCe3OjeR?=	NGj0UYI2OCCwTR?=	NE\aOGo1QCCq		NH7LXm5qdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	MUCyOVI4QTF7MR?=
769-P	NX[yZpNtSXCxcITvd4l{KEG\|c3H5	MVy1NEBvVQ>?	MmqyOFghcA>?		MVHpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>?	MX6yOVI4QTF7MR?=
786-O	MoDLRZBweHSxc3nzJGF{e2G7	MYW1NEBvVQ>?	NV\Mepp4PDhiaB?=		MmDabY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ?	Mnn0NlUzPzlzOUG=
Caki-1	NYjMcHRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfnRZozPS93MDDuUS=>	MWC0PEBp	NHziU3ZFVVOR	NGP5RYZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni	NI[w[20zPTF5NkO1OC=>
ACHN	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzZNlUwPTBibl2=	NXG2XVZFPDhiaB?=	M3rL[GROW09?	NVv1W4F3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=>	MWSyOVE4PjN3NB?=
769-P	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnqblkzPS93MDDuUS=>	MkfLOFghcA>?	MmPrSG1UVw>?	NXf3fVVWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=>	NEP4PYMzPTF5NkO1OC=>
Caki-1	MWrDc4xwdnliRn;ycYF1cW:wIFHzd4F6	MnPqOVAhdk1?	MlHkO{0yPCCm	MULEUXNQ	NF70fmR{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>?	M{fsVlI2OTd4M{W0
ACHN	M2qxUWNwdG:weTDGc5Ju[XSrb36gRZN{[Xl?	NV7NTWlUPTBibl2=	M3PzNlcuOTRiZB?=	Mle4SG1UVw>?	M37qW5N2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh	NVnSTocxOjVzN{[zOVQ>
769-P	MXHDc4xwdnliRn;ycYF1cW:wIFHzd4F6	M2\xOVUxKG6P	MoLoO{0yPCCm	NF;KbZdFVVOR	MoLod5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA>	NVXURXkyOjVzN{[zOVQ>
Caki-1	NWTkZ3BISXCxcITvd4l{KEG\|c3H5	NY\jbItFPTBibl2=	MUm0PEBp	M2LKdmROW09?	M1jCeYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NHmwe4MzPTF5NkO1OC=>
ACHN	MWHBdI9xfG:\|aYOgRZN{[Xl?	Mmq0OVAhdk1?	NFnO[YE1QCCq	M1nRd2ROW09?	M4LHfYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NIjVbIkzPTF5NkO1OC=>
769-P	NFvFfoRCeG:ydH;zbZMhSXO\|YYm=	NHq0WnY2OCCwTR?=	NEfINmc1QCCq	M4nYcmROW09?	MkXhbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M{HLPVI2OTd4M{W0
MDA-MB-231	MmDPUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6	NX\GTHBmOTEEoH7N	MkS3N:Kh\A>?	M{[0V2ROW09?	MWLhcJRmenNiY3XscEBud3KyaH;sc4d6yqB?	NWfubllmOjR6MUC0PVc>
BT-549	MliyUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6	MUSxNOKhdk1?	NH7z[48{yqCm	NIrVb2lFVVOR	NUfDTJI3[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg	NGT6R\|AzPDhzMES5Oy=>
MCF-7	Mn31UY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6	MXixNOKhdk1?	MljTN:Kh\A>?	NU\xWXVXTE2VTx?=	MnfnZYx1\XK\|IHPlcIwhdW:{cHjvcI9ogcLi	Mn76NlQ5OTB2OUe=
MCF-7	MWHGeY5kfGmxbjDBd5NigQ>?	M4X6TFUuPTBibl2=	NXrKd2QzOjRiaB?=	NGW1[IZFVVOR	Ml32doVlfWOnZDD0bIUhdGW4ZXygc4Yh\XiycnXzd4lwdiCxZjDFVu6yNCCSUjDhcoQhTm:6QUJCpC=>	M3GxZ\|I1OzZ4NEC3
CTS	NH;CXpVCeG:ydH;zbZMhSXO\|YYm=	M{X1NlDjiJN2MDDuUeKh	NF3GTmI1QCCq		MVnpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MkfrNlQzPDR2Mkm=
OCI-AML3	Mlr0RZBweHSxc3nzJGF{e2G7	MmTXNQKBmzRyIH7NxsA>	NIH6TXA1QCCq		MYfpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	Ml7TNlQzPDR2Mkm=
U937	M4PO[GFxd3C2b4Ppd{BCe3OjeR?=	MnHaNQKBmzRyIH7NxsA>	MnHIOFghcA>?		NYOz[2Q2cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NHXOfGwzPDJ2NESyPS=>
PC3	M{\XO2Fxd3C2b4Ppd{BCe3OjeR?=	MUmwMVExOCCwTR?=	M{frWlI1NzR6IHi=		MnjhbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NF7tb4czPDF4M{KzNC=>
PC3-AR	NYjqXWo4SXCxcITvd4l{KEG\|c3H5	MUOwMVExOCCwTR?=	NFP6VYMzPC92ODDo		MUXpcoR2[2W\|IHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MYWyOFE3OzJ\|MB?=
PC3	NUPWO446T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXWwMVExOCCwTR?=	NIjqPWozPC92ODDo		M3zYV4lv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25?	NIn2VI4zPDF4M{KzNC=>
PC3-AR	MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\sXVAuOTByIH7N	NF7yeHAzPC92ODDo		M4iyWIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG\|ZR?=	NISzPJIzPDF4M{KzNC=>
PC3	Mm\CSpVv[3Srb36gRZN{[Xl?	NHvlfXAxNTFyMDDuUS=>	M3np[\|I1KGh?		NV;X[nVPe3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4>	NEHTcGkzPDF4M{KzNC=>
PC3-AR	M1u3[GZ2dmO2aX;uJGF{e2G7	MlLxNE0yODBibl2=	MUCyOEBp		NEL5dWh{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM\|IheHKxdHXpci=>	M3f5OFI1OTZ\|MkOw
OS-RC-2	Mn:4R4VtdCCYaXHibYxqfHliQYPzZZk>	M{fPV\|AuOTByMDDuUS=>	NELROYszPC92OD:3NkBp	NUPkfFQ2TE2VTx?=	MmO3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NEHFR44zPDF2NEezOy=>
OS-RC-2	MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlW3OVAhdk1?	Mlm1OFghcA>?	Moi2SG1UVw>?	MmLrbY5lfWOnczDHNk9OKGG{cnXzeC=>	M3jpUlI1OTR2N{O3
OS-RC-2	M2jHXWFxd3C2b4Ppd{BCe3OjeR?=	M1zMVlUxKG6P	MY[0PEBp	NEf5[5pFVVOR	NGDzPI1qdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M{[5c\|I1OTR2N{O3
SK-N-AS	NHnS[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fhV\|DjiJN6MDDuUS=>	Mnu0OFghcA>?		NYnnO\|VkUUN3ME2yO{41KG6P	NIXWcXgzPDB7OEe5PS=>
SK-N-DZ	M{fiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rsS\|DjiJN6MDDuUS=>	NG\wXVE1QCCq		NWXyPFdvUUN3ME2yNU46KG6P	MmS5NlQxQTh5OUm=
SK-N-SH	NXe1TnZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHZNQKBmzhyIH7N	MVO0PEBp		M332bGlEPTB;N{KuN{BvVQ>?	MUeyOFA6QDd7OR?=
SK-N-BE	NFzlW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{G0WVDjiJN6MDDuUS=>	MXy0PEBp		MlLVTWM2OD15NT60JI5O	MYWyOFA6QDd7OR?=
SK-N-AS	M17WVGFxd3C2b4Ppd{BCe3OjeR?=	MW[w5qCUQDBibl2=	NIL4blQ1QCCq		M3jYOpBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	NYC5S\|JKOjRyOUi3PVk>
SK-N-DZ	NH\nTYFCeG:ydH;zbZMhSXO\|YYm=	M1fkbFDjiJN6MDDuUS=>	MYq0PEBp		NWXlUFhmeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v	MmjCNlQxQTh5OUm=
SK-N-SH	NFzabnZCeG:ydH;zbZMhSXO\|YYm=	Mk[xNQKBmzRyIH7N	MoDROFghcA>?		NEfie4Rxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44>	MmPGNlQxQTh5OUm=
SK-N-BE	M4W3UmFxd3C2b4Ppd{BCe3OjeR?=	MlPwNQKBmzRyIH7N	MWi0PEBp		MoLtdI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	NGPrenAzPDB7OEe5PS=>
SK-N-AS	MlqySpVv[3Srb36gRZN{[Xl?	NV;UU5VSOOLCk{iwJI5O	M{n6[\|Q5KGh?		M1vFeYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA>	NYfKcFJqOjRyOUi3PVk>
SK-N-DZ	NGHJWnpHfW6ldHnvckBCe3OjeR?=	M{flSVDjiJN6MDDuUS=>	M{PZWlQ5KGh?		M{K3PIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA>	MlnuNlQxQTh5OUm=
SK-N-SH	NV3wN482TnWwY4Tpc44hSXO\|YYm=	MWGw5qCUPDBibl2=	Ml\2OFghcA>?		MYTpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG\|ZTCzJIFv\CCSQWLQ	M1zKUlI1ODl6N{m5
SK-N-BE	NXX3cW5[TnWwY4Tpc44hSXO\|YYm=	MknzNQKBmzRyIH7N	NV\QTFE1PDhiaB?=		M{m0cYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA>	NEnlSpczPDB7OEe5PS=>
HCC-LM3	NVTacY5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmC1NU0yODByIH7N	MYqyOE81QC95MjDo	MXzEUXNQ	NF\nSIFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	Mn7xNlQxQTN7NU[=
HepG2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DXdlEuOTByMDDuUS=>	M4PVO\|I1NzR6L{eyJIg>	NGH0UHhFVVOR	MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NVnLepNJOjRyOUO5OVY>
SMMC-7721	M17F[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17OTlEuOTByMDDuUS=>	NXvX[IhXOjRxNEivO\|IhcA>?	M3W3RmROW09?	M{G5colvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NV;jRXpsOjRyOUO5OVY>
HCC-LM3	NXjBR4R{SXCxcITvd4l{KEG\|c3H5	MkXEOVAhdk1?	M3S1b\|Q5KGh?	NYeyWGZ7TE2VTx?=	MnOxbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk>	M{\BeFI1ODl\|OUW2
HepG2	MmjDRZBweHSxc3nzJGF{e2G7	M33Rc\|UxKG6P	NX72UnZ6PDhiaB?=	NE[2RXhFVVOR	MlW0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk>	Ml3iNlQxQTN7NU[=
SMMC-7721	MlnSRZBweHSxc3nzJGF{e2G7	MYK1NEBvVQ>?	MXy0PEBp	NYr6VoNRTE2VTx?=	M3HDNYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6	MnPhNlQxQTN7NU[=
HCC-LM3	MoPPSpVv[3Srb36gRZN{[Xl?	NUjKVo9RPTBxMUCwJI5O	NWPkN2x3OjRiaB?=	NWXhcVBiTE2VTx?=	MVrk[YNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi	MX[yOFA6Ozl3Nh?=
HepG2	MmrpSpVv[3Srb36gRZN{[Xl?	M2TGSlUxNzFyMDDuUS=>	NFHMWIQzPCCq	MkXXSG1UVw>?	MnzP[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?=	MViyOFA6Ozl3Nh?=
SMMC-7721	M1TWWmZ2dmO2aX;uJGF{e2G7	NXn2PYFKPTBxMUCwJI5O	MkLmNlQhcA>?	NY\DSlZ2TE2VTx?=	NV3G[pli\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=>	NFe0UXAzPDB7M{m1Oi=>
HCC-LM3	MmrzSpVv[3Srb36gRZN{[Xl?	M{XRR\|UxNzFyMDDuUS=>	NFrrZ5czPCCq	MljISG1UVw>?	MkX5[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>?	NXrlZ\|RtOjRyOUO5OVY>
HepG2	M2G3NGZ2dmO2aX;uJGF{e2G7	M4LOWlUxNzFyMDDuUS=>	M{XIblI1KGh?	MlHESG1UVw>?	NE\STZVld3ewcnXneYxifGW\|IFLjcE15VCCneIDy[ZN{cW:w	MWCyOFA6Ozl3Nh?=
SMMC-7721	MXvGeY5kfGmxbjDBd5NigQ>?	M1KyW\|UxNzFyMDDuUS=>	MUKyOEBp	Mo\vSG1UVw>?	Mmrn[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>?	MojuNlQxQTN7NU[=
FaDu	NETXTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV2xNFDjiIWwTR?=	MXy4M\|ExNzF{IHi=		NE\VdY5lcXOybHH5[YQh[SC\|aXfubYZq[2GwdDDhcoQheHKxbH;u[4VlKEd{L12gZZJz\XO2IHH0JFgh[W6mIEGy5qCGcCCyb4P0JJJmdGWjc3W=	MnfENlQxOjZ2OEK=
FaDu	M1TpU2Z2dmO2aX;uJGF{e2G7	M2qze\|ExOOLChX7N	MX6yM\|QwQC9zMjDo		M{K4NYlv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w	NHXxV2QzPDB{NkS4Ni=>
PC-3	NYTrOppPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7FNE0yOCEQvF2=	NGjhW3ozPC92OD:3NkBp		NVK3VnRscW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NV3NW2E3OjN7OUGyNVY>
LNCaP	Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjJNE02KM7:TR?=	NIS1WXYzPC92OD:3NkBp		M2H1W4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MWmyN\|k6OTJzNh?=
RWPE-1	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX6wMVIxKM7:TR?=	M1GzflI1NzR6L{eyJIg>		MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NHP5ZZYzOzl7MUKxOi=>
Capan-1	MV3GeY5kfGmxbjDBd5NigQ>?	MV:yOU82OC9zMECgcm0>	MYW4M\|I1NzR6IHi=	M3vaNWROW09?	M2XUNYRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW\|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne=	M1;qfVI{QTJ{OEi2
L3.6pl	MVfGeY5kfGmxbjDBd5NigQ>?	M4HVelI2NzVyL{GwNEBvVQ>?	MoHaPE8zPC92ODDo	NUnVdIlWTE2VTx?=	NWjRWmZJ\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=>	MkHNNlM6OjJ6OE[=
CFPAC-1	Mmm4SpVv[3Srb36gRZN{[Xl?	MkW0NlUwPTBxMUCwJI5O	NFHCfZY5NzJ2L{S4JIg>	MlPvSG1UVw>?	M2D5U4Rwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW\|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne=	Mnv2NlM6OjJ6OE[=
Capan-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1e1XVI2NzVyL{GwNEBvVQ>?	Ml\lOFghcA>?	NYT6WIszTE2VTx?=	NV76UGdbemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MYKyN\|kzOjh6Nh?=
L3.6pl	NHPucHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzWNlUwPTBxMUCwJI5O	MUi0PEBp	NIjIboZFVVOR	NEjIU25z\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NUjmWlA2OjN7MkK4PFY>
CFPAC-1	NGfM[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXmyOU82OC9zMECgcm0>	NYnxPHpIPDhiaB?=	MmqzSG1UVw>?	NYj5W4k4emWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NIfrRpAzOzl{Mki4Oi=>
Capan-1	M1vwOGFxd3C2b4Ppd{BCe3OjeR?=	M{PPNlI2NzVyL{GwNEBvVQ>?	NVezOopJPDhiaB?=	MlnNSG1UVw>?	MYrpcoR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	Ml3UNlM6OjJ6OE[=
L3.6pl	NXvi[ZAxSXCxcITvd4l{KEG\|c3H5	M1G4NFI2NzVyL{GwNEBvVQ>?	NUHnS\|VpPDhiaB?=	NFfpepJFVVOR	NWna[lhPcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MWqyN\|kzOjh6Nh?=
CFPAC-1	MYPBdI9xfG:\|aYOgRZN{[Xl?	MnP6NlUwPTBxMUCwJI5O	M37tT\|Q5KGh?	M2CybGROW09?	MVvpcoR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1uzdVI{QTJ{OEi2
HN22	M2LCcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3aTFczOC1{MDDuUS=>	M4DpfVI1NzR6IHi=	M3HnRWROW09?	NELQXYlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz	MkL3NlM5Pzd{M{W=
HSC4	NWHTVmFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPXNE0zOCCwTR?=	NETzTW4zPC92ODDo	M1rTXmROW09?	MYfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy	NVnPV4xxOjN6N{eyN\|U>
HN22	NVnySpNiSXCxcITvd4l{KEG\|c3H5	NFHDOm0xNTJyIH7N	NVvUW2E3PDhiaB?=	NXnuUHJOTE2VTx?=	NYTvOlg2cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MnPZNlM5Pzd{M{W=
HSC4	M2HOTmFxd3C2b4Ppd{BCe3OjeR?=	M3zjOFAuOjBibl2=	NUnLN\|lKPDhiaB?=	NVLUVnd6TE2VTx?=	MmjlbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MXqyN\|g4PzJ\|NR?=
HN22	MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVWwMVIxKG6P	M1LNfVQ5KGh?	MknRSG1UVw>?	NVG5b44zcW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh	NHPieY0zOzh5N{KzOS=>
HSC4	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvaW4dLOC1{MDDuUS=>	Mmi5OFghcA>?	M4iyVGROW09?	NISydolqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA>	M1i4dFI{QDd5MkO1
HN22	NFfiZ3RHfW6ldHnvckBCe3OjeR?=	MYWwMVIxKG6P	MkDxOFghcA>?	MYjEUXNQ	Mn\Hd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg	MlvpNlM5Pzd{M{W=
HSC4	M2P6O2Z2dmO2aX;uJGF{e2G7	M4rJ[VAuOjBibl2=	NWrHUXA2PDhiaB?=	M1jIfWROW09?	NYrmdFc{e3WycILld5NmeyCVcEGg[ZhxemW\|c3nvcuKh	Mk\hNlM5Pzd{M{W=
Cal62	NY\icpRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XnS2lEPTB;M{OgxtEhPCCwTR?=	NF7Ed4gzOzh{NEC2OC=>
Hth7	MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nmfWlEPTB;MUWgxtEhOiCwTR?=	M1rNfVI{QDJ2ME[0
Hth83	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTN2INMxJFUhdk1?	Mk\jNlM5OjRyNkS=
C643	M2HKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTdzINMxJFExKG6P	MXuyN\|gzPDB4NB?=
SW1736	M{L4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHUTWM2OD1\|NTFCtUA5KG6P	MXOyN\|gzPDB4NB?=
T241	NUL5fnFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;PRW5KSzVyPU[1JOKyKDdibl2=	M4HmdVI{QDJ2ME[0
T351	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljoTWM2OD13MDFCtUAyOCCwTR?=	M1\rUlI{QDJ2ME[0
BHP2-7	NXPkTW84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnqyTWM2OD1\|NzFCtUA3KG6P	NITrWVUzOzh{NEC2OC=>
T238	M3TCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rXSGlEPTB;MTy1NFAhyrFiMkCwJI5O	MkOxNlM5OjRyNkS=
HCT8	NYHQV2xQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV\qOY1KPzJiaB?=	NV7yW\|d3TE2VTx?=	M2nO[GlEPTB;MUKuPgKBkcLz4pEJNU46KG6P	MmXyNlMzQTl\|OEi=
H630	MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYS3NkBp	MmHFSG1UVw>?	M{HlZWlEPTB;MUKuOQKBkcLz4pEJN{4yKG6P	NEnu[XkzOzJ7OUO4PC=>
cH630 5-FU-res	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWS3NkBp	M4TI[WROW09?	NFPySoVKSzVyPUG1MlXjiIoEsfMAjVEvOiCwTR?=	NWfnUWhrOjN{OUmzPFg>
HCT116	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVHw[ZBGPzJiaB?=	NI\hTVRFVVOR	NW\FfnBbUUN3ME2xNE446oDLwsJihKkzNjJibl2=	MXSyN\|I6QTN6OB?=
HCT116 p53−/−	MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn\WO\|IhcA>?	NF3FS29FVVOR	MW\JR\|UxRThwNvMAjeKy6oDLMT63JI5O	M1nWb\|I{Ojl7M{i4
dHCT116 p21−/−	M3\GTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWe3NkBp	M3HOTmROW09?	NVz6eZRJUUN3ME21MlnjiIoEsfMAjVEvOyCwTR?=	NUO0bpA5OjN{OUmzPFg>
HT29	NVzQPZBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4DjWlczKGh?	MmnaSG1UVw>?	M4jZdGlEPTB;MU[uN-KBkcLz4pEJNk4{KG6P	MYSyN\|I6QTN6OB?=
LoVo	NXPNTHVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV3NdWNLPzJiaB?=	NHHi[5RFVVOR	MnzVTWM2OD13LkJihKnDueLCiUCuOkBvVQ>?	M13wUVI{Ojl7M{i4
RKO	NHnUUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4ntUFczKGh?	M2rU[mROW09?	M{n3eGlEPTB;Nz655qCKyrIkgJmyMlIhdk1?	NE[zO3EzOzJ7OUO4PC=>
SW480	MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYfZZ4dsPzJiaB?=	MY\EUXNQ	MkHBTWM2OD1zNz615qCKyrIkgJmwMlghdk1?	Mn;PNlMzQTl\|OEi=
eSW620	NH;oNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWm3NkBp	MkCwSG1UVw>?	NHfNbXBKSzVyPUmuNgKBkcLz4pEJNk4yKG6P	NGHmeHkzOzJ7OUO4PC=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

In vivo

In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. ^[2]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
Concentrations: 50 nM
Incubation Time: 48 hours
Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 10⁴ cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
(Only for Reference)

Animal Research:^[2]

- Collapse

Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (10⁷ cells) or A549 (5 × 10⁶ cells), H69 (2.5 × 10⁶ cells), BK-T (6.5 × 10⁶), H526 (10 × 10⁶), and RG1 (10 × 10⁶) cells
Dosages: 10 mg/kg, 20 mg/kg
Administration: Administered via i.p. injection
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+48% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Panobinostat (LBH589) SDF

Molecular Weight	349.43
Formula	C₂₁H₂₃N₃O₂
CAS No.	404950-80-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NVP-LBH589
Smiles	CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04341311	Recruiting	Drug: Marizomib\|Drug: Panobinostat	Diffuse Intrinsic Pontine Glioma\|Pediatric Brainstem Glioma\|Pediatric Brainstem Gliosarcoma Recurrent\|Pediatric Cancer\|Pediatric Brain Tumor\|Diffuse Glioma	Dana-Farber Cancer Institute\|Celgene\|Secura Bio	August 2020	Phase 1
NCT03632317	Withdrawn	Drug: Panobinostat\|Drug: Everolimus	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	October 2019	Phase 2
NCT03982134	Withdrawn	Drug: PDR001\|Drug: Panobinostat	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	September 2019	Phase 1
NCT04326764	Recruiting	Drug: Panobinostat	Acute Myeloid Leukaemia (AML)\|Myelodysplastic Syndromes (MDS)	Goethe University\|Jan J. Cornelissen (HOVON-SAKK)\|Sebastian Giebel (PALG)	July 24 2018	Phase 3
NCT03515915	Unknown status	--	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	April 23 2018	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to reconstitute the compound for in vivo mice study?
Answer:
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Panobinostat (LBH589)